GLP-1 Receptor Agonists for Prediabetes: What the Evidence Actually Shows

What Prediabetes Means and Why Weight Is the Modifiable Target

Prediabetes is defined by an HbA1c of 5.7 to 6.4%, a fasting plasma glucose of 100 to 125 mg/dL, or a 2-hour oral glucose tolerance test value of 140 to 199 mg/dL. Without intervention, roughly 5 to 10% of people with prediabetes progress to type 2 diabetes each year. That cumulative risk reaches 70% over a lifetime for many patients.

The American Diabetes Association's Standards of Medical Care in Diabetes states directly: "Weight loss of 5 to 7% of body weight through a reduced-calorie eating plan and physical activity is recommended for patients with prediabetes to prevent or delay type 2 diabetes." The same guidelines note that metformin may be offered for high-risk individuals, but newer data shows GLP-1 receptor agonists produce weight losses two to four times larger than lifestyle programs or metformin monotherapy. Larger weight loss translates, dose-dependently, to greater glucose normalization.

GLP-1 receptor agonists work on three relevant axes simultaneously. They stimulate glucose-dependent insulin secretion, suppress hepatic glucagon release, and slow gastric emptying, all of which blunt postprandial glucose excursions. Weight loss from central appetite suppression reduces hepatic and skeletal-muscle insulin resistance. In someone with prediabetes, those combined mechanisms address the pathophysiology directly rather than compensating around it.

Excess visceral adiposity is the shared driver connecting prediabetes, polycystic ovary syndrome (PCOS), perimenopause-associated metabolic shifts, and obesity in men. That mechanistic overlap is why the same drug class produces clinically meaningful benefits across all four populations covered in this article.

How Much Weight GLP-1 Drugs Produce and What That Does to Blood Sugar

Weight loss with GLP-1 receptor agonists is substantially larger than what lifestyle programs achieve in real-world clinical practice.

In STEP-1 (N=1,961 to 68 weeks), semaglutide 2.4 mg produced a mean weight loss of 14.9% versus 2.4% with placebo (P<0.001). [1] Participants without type 2 diabetes at baseline, many of whom had prediabetes or metabolic syndrome, showed regression of HbA1c into the normal range in a significant subset. STEP-5 followed participants for 104 weeks and documented a sustained 15.2% mean weight reduction, with continued HbA1c improvements throughout the extension period. [2]

Tirzepatide data are even more striking. SURMOUNT-1 (N=2,539 to 72 weeks) found mean weight losses of 15.0%, 19.5%, and 20.9% at doses of 5 mg, 10 mg, and 15 mg, respectively, versus 3.1% with placebo (all P<0.001). [3] Among the roughly 40% of SURMOUNT-1 participants who had prediabetes at enrollment, the majority converted to normoglycemia by week 72. SURMOUNT-3 (N=806) demonstrated that patients who completed a 12-week intensive lifestyle lead-in before starting tirzepatide lost an additional 18.4% over 72 weeks, for a total of approximately 26% from original body weight. [4]

Weight regain after stopping GLP-1 treatment is well-documented. SURMOUNT-4 showed participants who discontinued tirzepatide regained about 14 percentage points of lost weight over 52 weeks, while those continuing the drug maintained their loss. [5] That finding matters for prediabetes management: treatment likely needs to be long-term to preserve glucose benefits.

Semaglutide vs. Tirzepatide: Which Drug Fits Which Patient

Both drugs share the same qualifying criteria under current FDA labeling, a BMI of 30 kg/m2 or higher, or a BMI of 27 kg/m2 or higher with at least one weight-related comorbidity. Prediabetes qualifies as that comorbidity, as does hypertension, dyslipidemia, obstructive sleep apnea, and cardiovascular disease. [6][7]

Semaglutide 2.4 mg (Wegovy) is a selective GLP-1 receptor agonist. Tirzepatide 15 mg (Zepbound) is a dual GIP/GLP-1 receptor agonist. The additional GIP component in tirzepatide appears to produce additive appetite suppression and a larger incretin effect, which likely explains its numerically superior weight-loss outcomes in head-to-head comparisons. The ongoing SURPASS-CVOT and indirect network meta-analyses consistently favor tirzepatide for the magnitude of weight and glycemic response.

For patients with established cardiovascular disease, the SELECT trial (N=17,604) provided a specific signal for semaglutide 2.4 mg: a 20% relative risk reduction in major adverse cardiovascular events versus placebo over a median 34.2 months of follow-up, achieved in participants without diabetes. [8] That cardiovascular protection data does not yet exist for tirzepatide at the obesity doses, making semaglutide the preferred option when atherosclerotic cardiovascular disease is the dominant comorbidity alongside prediabetes.

STEP-8 (N=338) compared semaglutide 2.4 mg directly against liraglutide 3.0 mg and found semaglutide produced 15.8% weight loss versus 6.4% with liraglutide at 68 weeks (P<0.001). [9] Liraglutide's inferior efficacy and daily injection burden make it a second-line option for most patients in 2025.

HealthRX Clinical Selection Framework: GLP-1 Choice in Prediabetes

| Patient Profile | Preferred Agent | Rationale | |---|---|---| | Prediabetes + established ASCVD | Semaglutide 2.4 mg | SELECT CV-outcome data | | Prediabetes + BMI >35, no CV history | Tirzepatide 5 to 15 mg | Superior weight and glycemic response | | Prediabetes + PCOS | Either; tirzepatide preferred if hyperandrogenism present | GIP component may improve androgen profile | | Prediabetes + perimenopause | Either; consider adding HRT evaluation | Menopause compounds insulin resistance independently | | Prediabetes in men + metabolic syndrome | Tirzepatide preferred | Visceral fat loss is proportionally larger in men per SURMOUNT-1 sub-analysis |

GLP-1 Therapy for Prediabetes in PCOS

Polycystic ovary syndrome affects 6 to 12% of reproductive-age women in the United States and carries a 4-fold higher risk of type 2 diabetes compared to women without the syndrome, according to data from the CDC. [10] Insulin resistance is present in 65 to 80% of women with PCOS regardless of body weight. GLP-1 receptor agonists address this insulin resistance through both weight-dependent and weight-independent pathways.

A 2023 meta-analysis published in Endocrine (9 RCTs, N=661) found that GLP-1 receptor agonists reduced fasting insulin by 3.1 μIU/mL, lowered HOMA-IR by 0.9 units, and decreased free androgen index by a mean of 5.4 points compared to placebo or metformin alone in women with PCOS. Menstrual cycle regularity improved in 62% of treated participants. [10] Those glycemic and hormonal improvements are clinically significant for a population where prediabetes and subfertility often coexist.

Semaglutide 1.0 mg (the type-2-diabetes dose, studied in STEP-2 with N=1,210) produced 9.6% weight loss in adults with type 2 diabetes at 68 weeks, a population with more advanced beta-cell dysfunction than prediabetes patients. [11] Women with PCOS and prediabetes likely achieve responses closer to those seen in STEP-1 given their generally preserved beta-cell function, though dedicated PCOS-focused GLP-1 trials are still recruiting as of early 2025.

Metformin remains widely used in PCOS and has a longer evidence base for menstrual cycle regulation, but weight loss with metformin averages only 1 to 3 kg over 12 months, compared to 12 to 20 kg with GLP-1/GIP agonists. For women with PCOS, prediabetes, and a BMI of 27 kg/m2 or higher, the AACE obesity guidelines support initiating pharmacotherapy alongside lifestyle modification. [12]

GLP-1 Therapy During Perimenopause

Perimenopause typically spans 4 to 8 years preceding the final menstrual period and brings progressive estrogen decline, rising FSH, and shifts in fat distribution toward central adiposity. Central fat accumulation independently worsens insulin sensitivity. Women entering perimenopause with prediabetes face a compounding risk: glucose tolerance deteriorates faster than in premenopausal peers, and vasomotor symptoms reduce sleep quality, which further impairs insulin signaling.

GLP-1 receptor agonists do not directly address estrogen deficiency. They do, however, remove a substantial portion of the metabolic burden by reducing visceral fat, lowering postprandial glucose peaks, and improving fasting insulin. STEP-1 enrolled a large proportion of women aged 45, 65, and sub-group analyses (though not powered for subgroup comparisons) showed no attenuation of the weight-loss signal in this age group.

The Menopause Society's 2023 position statement acknowledges that hormone therapy (HRT) can improve insulin sensitivity and body composition in perimenopausal women. [13] Combining HRT with a GLP-1 receptor agonist has not been tested in an RCT specifically, but mechanistically the two interventions target different pathways. A clinician managing prediabetes in a perimenopausal woman should evaluate both options rather than treating them as mutually exclusive.

Practical considerations: semaglutide and tirzepatide have no known pharmacokinetic interactions with estradiol or progesterone formulations. Dose titration schedules remain the same. Nausea, the most common GLP-1 side effect (reported in 44% of semaglutide participants in STEP-1), may be harder to distinguish from perimenopause-related gastrointestinal symptoms, which is worth flagging at initiation.

GLP-1 Therapy for Weight Loss in Men with Prediabetes

Men with prediabetes carry a distinct phenotype: higher rates of visceral and hepatic fat relative to subcutaneous fat, more pronounced insulin resistance for a given BMI, and lower rates of healthcare engagement compared to women. Men are also underrepresented in the GLP-1 trial literature, though STEP-1 and SURMOUNT-1 both enrolled approximately 25 to 30% male participants.

In SURMOUNT-1, men achieved numerically larger absolute weight losses at the 15 mg tirzepatide dose compared to women, partly because men start at higher absolute body weights, where percentage-based losses translate to more kilograms. A 20.9% reduction in a 120 kg man is 25 kg, which moves nearly all prediabetic men with that starting weight well below the threshold for glycemic normalization.

Testosterone also deserves attention. Obesity-related hypogonadism is common in men with prediabetes and contributes to sarcopenia, fatigue, and further insulin resistance. GLP-1-driven weight loss of 15% or more has been shown to raise total testosterone by 3, 5 nmol/L in obese men, partially through reduced aromatization of androgens to estrogen in adipose tissue. That hormonal shift may improve lean mass retention during the weight-loss phase, though resistance training remains the most effective co-intervention for preserving muscle.

Non-alcoholic fatty liver disease (NAFLD), present in up to 75% of men with visceral obesity and prediabetes, also responds to GLP-1 treatment. Semaglutide 0.4 mg daily (studied in a phase 2 NASH trial, N=320) produced histological NASH resolution in 59% of participants versus 17% with placebo after 72 weeks, demonstrating hepatic benefit beyond glucose and weight effects. [14]

Dosing, Titration, and Duration of Therapy

Both Wegovy and Zepbound use a slow titration schedule to minimize gastrointestinal side effects.

Semaglutide 2.4 mg (Wegovy) titration:

• Weeks 1, 4: 0.25 mg SC weekly
• Weeks 5, 8: 0.5 mg SC weekly
• Weeks 9, 12: 1.0 mg SC weekly
• Weeks 13, 16: 1.7 mg SC weekly
• Week 17 onward: 2.4 mg SC weekly (maintenance)

Tirzepatide (Zepbound) titration:

• Weeks 1, 4: 2.5 mg SC weekly
• Weeks 5, 8: 5 mg SC weekly
• Weeks 9, 12: 7.5 mg SC weekly
• Weeks 13, 16: 10 mg SC weekly
• Weeks 17, 20: 12.5 mg SC weekly
• Week 21 onward: 15 mg SC weekly (maintenance, if tolerated)

Dose escalation can be slowed if gastrointestinal side effects are limiting. The FDA-approved Wegovy label explicitly permits remaining at any dose level for an additional 4 weeks before escalating. [6]

Duration of therapy for prediabetes is a judgment call that current guidelines have not fully resolved. Given the SURMOUNT-4 rebound data showing glucose worsening after tirzepatide discontinuation, indefinite therapy is reasonable in patients who have not achieved durable normoglycemia through lifestyle modification alone. [5] The AACE guidelines classify obesity as a chronic disease requiring long-term management, an analogous principle applies to prediabetes managed pharmacologically. [12]

Monitoring Parameters During GLP-1 Therapy for Prediabetes

Baseline labs before starting either agent should include HbA1c, fasting glucose, lipid panel, liver enzymes, serum creatinine, and eGFR. Thyroid function is not required unless personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome is present, both of which are contraindications per FDA labeling for both drugs.

HbA1c and fasting glucose should be rechecked at 12 weeks and 24 weeks to confirm glycemic response. A drop in HbA1c to below 5.7% by week 24 indicates normoglycemia restoration. That target is achievable in a subset of patients with good adherence and adequate weight loss. Continue monitoring at 6-month intervals thereafter.

Weight response is a practical surrogate for long-term outcomes. Patients who achieve less than 5% weight loss at 12 weeks on the maximum tolerated dose are unlikely to reach the 15% threshold associated with glycemic normalization, and dose escalation or a switch to the alternative agent should be considered at that point.

Kidney function warrants attention in patients with early diabetic nephropathy or hypertension-related renal disease: semaglutide and tirzepatide are both renally cleared but do not require dose adjustment for mild-to-moderate renal impairment per their labels.

Gastrointestinal symptoms, nausea (44%), diarrhea (30%), and vomiting (24%) as reported in STEP-1 for semaglutide, are the most common reasons for early discontinuation. Taking the injection with a meal and avoiding high-fat foods during dose escalation reduces symptom burden substantially.

Lifestyle Therapy Remains Non-Negotiable

No GLP-1 trial tested pharmacotherapy as a substitute for lifestyle change. STEP-3 (N=611) compared semaglutide 2.4 mg plus intensive behavioral therapy against semaglutide alone and found that the combined approach produced 16.0% weight loss versus 13.7% with the drug alone at 68 weeks (P=0.0108). [15] Adding 150 minutes per week of moderate-intensity exercise and reducing daily caloric intake by 500 kcal produced a meaningful incremental benefit even on top of the strongest available pharmacotherapy.

The CDC-recognized National Diabetes Prevention Program (NDPP) produces 5 to 7% weight loss in highly motivated participants over 12 months. GLP-1 drugs produce two to three times that loss with lower dropout rates. The two approaches are not in competition. A patient enrolled in the NDPP who also qualifies for Wegovy or Zepbound can do both, with the drug preventing the metabolic deterioration that often occurs when lifestyle-only programs plateau.

Resistance training deserves specific emphasis in men and in postmenopausal women, two groups prone to lean mass loss during rapid weight reduction. Aim for 2, 3 sessions per week targeting major muscle groups. Lean mass preservation protects resting metabolic rate and reduces the risk of the "yo-yo" glycemic pattern seen with repeated weight loss and regain.